Baxter International, Inc. Reports Results of ADVATE Real-World Experience From Worldwide Post-Marketing Database of Hemophilia A Patients
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today presented two comprehensive analyses supporting the proven clinical and real-world results of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] during the 24th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Amsterdam, The Netherlands. The presentations include two complementary studies of the ADVATE profile, including an analysis of post-marketing data from approximately 1,200 hemophilia A patients across 15 countries as well as safety findings from a 10-year database of 12 clinical trials.
Help employers find you! Check out all the jobs and post your resume.
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) today presented two comprehensive analyses supporting the proven clinical and real-world results of ADVATE [Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method] during the 24th Annual Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Amsterdam, The Netherlands. The presentations include two complementary studies of the ADVATE profile, including an analysis of post-marketing data from approximately 1,200 hemophilia A patients across 15 countries as well as safety findings from a 10-year database of 12 clinical trials.
Help employers find you! Check out all the jobs and post your resume.